TITLE

FDA Approves Eyetech/Pfizers Macugen

PUB. DATE
January 2005
SOURCE
Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic drugs to specifically target vascular endothelial growth factor, a protein that acts as a signal in triggering the abnormal blood vessel growth. Macugen is administered in a 0.3-mg dose once every six weeks by intravitreal injection.
ACCESSION #
15822087

 

Related Articles

  • Pipeline.  // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12 

    The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • New Drug Treats Age-Related Macular Degeneration.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Announces the approval given by the U.S. Food and Drug Administration to the drug Macugen from Eyetech Pharmaceuticals Inc. and Pfizer Inc. to slow vision loss in people with wet age-related macular degeneration (AMD). Overview of the therapeutic application of the drug targeting vascular...

  • Injection approved for macular degeneration.  // Drug Topics;1/10/2005, Vol. 149 Issue 1, p8 

    Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.

  • FDA committee votes 10-0 to recommend two retina therapeutics for approval for new indications.  // Ocular Surgery News;8/25/2012, Vol. 30 Issue 16, p1 

    No abstract available.

  • Remoxy: more work needed for FDA approval.  // Reactions Weekly;7/9/2011, Issue 1359, p3 

    The article reports on the rejection received by Pfizer from the U.S. Food and Drug Administration (FDA) for its extended-release formulation Remoxy.

  • Celebrex Loses FAP Indication.  // BioWorld Today;6/11/2012, Vol. 23 Issue 112, p6 

    The article reports on the decision of the U.S. Food and Drug Administration to pull out its 12-year-old accelerated approval for Celebrex, the drug for familial adenomatous polyposis (FAP) from Pfizer Inc. because the postmarketing study required to verify the clinical benefit was not completed.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics